


# Lessons learned from COBIS

**Bon-Kwon Koo, MD, PhD**

Seoul National University Hospital, Seoul, Korea



# COBIS studies


- Investigator-initiated nation wide multicenter registry studies for **CO**ronary **BI**furcation **S**tenting
- Endorsed by Korean Society of Interventional Cardiology
- Sponsored and managed by Korean Bifurcation Club (COBIS III)

	COBIS I	COBIS II	COBIS III
<b>Patients No.</b>	1691	2897	2648
<b>Enrollment period</b>	2004.1~2006.6	2003.1 ~ 2009.12	2010.1 ~ 2014.12
<b>Inclusion</b>			
Main vessel Diameter, mm	≥ 2.5	≥ 2.5	≥ 2.5
Side branch Diameter, mm	≥ 2.0	≥ 2.3	≥ 2.3
Left main bifurcation	X	0	0
<b>DES generation</b>	1 <sup>st</sup>	1 <sup>st</sup> + 2 <sup>nd</sup>	2 <sup>nd</sup> only
<b>Median Follow-up Duration</b>	25 months	38 months	53 months


# What makes the difference?

## Device? Concept? Technique?

### TLF in LM bifurcation



### TLF in non-LM bifurcation




# What makes the difference?

Device? Concept? Technique?

- Safer access: More trans-radial approach
- Better stents and better stenting technique
- Better PCI technique: Better kissing, NC balloon, POT
- Better concept: imaging guidance, SB relevance
- Better risk stratification: SB occlusion, risk stratification

## COBIS Registry

# Transradial vs. Transfemoral for Bifurcation PCI





- LM bifurcation lesions from COBIS II (N=853)
- Transradial (N=212, 24.9%) vs. Transfemoral (N=641)
- Propensity score-matched analysis (1:2 ratio, 161 pairs)

	Transradial (N=161)	Transfemoral (N=322)	Adjusted HR (95% CI)	p
<b>MACE</b>	14 (8.7)	37 (11.5)	0.48 (0.22-1.03)	0.06
Cardiac death	4 (2.5)	5 (1.6)	0.33 (0.02-4.97)	0.42
Cardiac death or MI	7 (4.3)	8 (2.5)	1.42 (0.35-5.69)	0.62
<b>TLR</b>	7 (4.3)	32 (9.9)	0.30 (0.11-0.81)	0.02
<b>TIMI major or minor bleeding</b>	<b>4 (2.5)</b>	<b>27 (8.4)</b>		<b>0.01</b>


# Korean Bifurcation Pooled Cohort

## 1<sup>st</sup> vs. 2<sup>nd</sup> generation DES



# COBIS III registry



## Clinical outcomes among 2<sup>nd</sup> generation DES





# COBIS III registry

## Clinical outcome among 2<sup>nd</sup> generation DES

### SB No treatment group




### SB Treatment group






# What is the best 2-stent technique?

TAP technique? Culotte technique? DK crush technique?




# What is the best 2-stent technique?

- N=673, treated with 2-stent technique (exclusion: kissing or V-stenting)



# What is the best 2-stent technique?


- N=673, treated with 2-stent technique (exclusion: kissing or V-stenting)




## COBIS III registry

# What is the best 2-stent technique?

1-stenting  
82.8%




Crush Technique  
53.7%



# COBIS III registry

## What is the best 2-stent technique?



Numbers at risk

	0	1	2	3	4	5
Crush	244	210	187	152	108	64
T-stenting	125	104	94	85	66	39
Culotte	31	29	26	23	13	10
Kissing	41	35	32	27	17	11

Kang JH. KBC workshop 2019

# Insight from COBIS II registry

## What is the best 2-stent technique?

Subgroup	Patients	TLR (%)		Favor SB first	Favor MV first	Hazard ratio (95% CI)	p value	p for Interaction
		SB first	MV first					
MV RD								0.52
≥3.25 mm	217	12/120 (10.0)	12/97 (12.4)			0.80 (0.36-1.78)	0.59	
<3.25 mm	456	40/303 (13.2)	19/153 (12.4)			1.09 (0.63-1.88)	0.77	
SB RD								0.54
≥2.5 mm	276	20/151 (13.2)	19/125 (15.2)			0.92 (0.49-1.72)	0.79	
<2.5 mm	397	32/272 (11.8)	12/125 (9.6)			1.23 (0.63-2.38)	0.55	
SB RD > MV RD								0.78

Subgroup	Patients	TLR (%)		Favor SB first	Favor MV first	Hazard ratio (95% CI)	p value	p for Interaction
		SB first	MV first					
MV DS								0.04
≥70%	257	22/156 (14.1)	8/101 (7.9)			1.94 (0.86-4.36)	0.11	
<70%	416	30/267 (11.2)	23/149 (15.4)			0.71 (0.41-1.22)	0.22	
SB DS > MV DS								0.008
Yes	252	17/189 (9.0)	12/63 (19.0)			0.44 (0.21-0.92)	0.03	
No	420	35/234 (15.0)	19/186 (10.2)			1.54 (0.88-2.68)	0.13	
MV Lesion Length								0.01
≥18 mm	329	36/215 (16.7)	11/114 (9.7)			1.79 (0.91-3.53)	0.09	
<18 mm	344	16/208 (7.7)	20/136 (14.7)			0.53 (0.27-1.01)	0.05	

“MORE severe lesion FIRST” strategy for cases requiring systematic 2 stenting.

≥65°	293	27/167 (16.2)	14/126 (11.1)			1.53 (0.80-2.92)	0.20
<65°	380	25/256 (9.8)	17/124 (13.7)			0.72 (0.39-1.33)	0.29

0.1 1 10

# What makes the difference?

Device? Concept? Technique?

- Safer access: More trans-radial approach
- Better stents and better stenting technique
- **Better PCI technique: Better kissing, NC balloon....**
- Better concept: Imaging guidance, SB relevance
- Better risk stratification: SB occlusion, risk stratification

# “KISS” for 1-stent technique: Good or Bad?

	Number Design	Primary endpoint	Outcomes	Results	Memo
Niemela M (NORDIC III) Circulation 2011	N=477 RCT	6-mo MACE	FKB 2.9%, non-FKB 2.9% P=NS	<b>Neutral</b>	
Gwon HC (COBIS I) Heart 2012	N=1,065 Registry	2-year MACE	FKB 9.5%, non-FKB 4.5% p=0.02	<b>Bad</b>	Higher MV TLR in FKB group
Yamawaki M Circ J 2014	N=253 Registry	3-year MACE	FKB 14.6% vs. non-FKB 6.9% p=0.07	<b>Bad</b>	Higher MV restenosis in FKB-group
Kim TH Int J Cardiol 2014	N=251 Registry	3-year MACE	FKB HR=0.40 (95% CI 0.19–0.84), p=0.015	<b>Good</b>	ACS patients
Biondi-Zoccai G Heart Vessels 2014	N=2,813 Registry	2-year MACE	HR=1.01 (0.80–1.23) p=0.91	<b>Neutral</b>	
Gao Z Chin Med J 2015	N=790 Registry	4-year MACE	FKB: 7.8%, non-FKB 10.0% p=0.33	<b>Neutral</b>	Left main bifurcation
Kim YH (CROSS) JACC CVI 2015	N=306 RCT	1-year MACE	FKB 14.0%, non-FKB 11.6% p=0.57	<b>Bad</b>	Higher MV restenosis in FKB group
Yu CW (COBIS II) JACC CVI 2015	N=1,901 Registry	3-year MACE	HR=0.50 (95% CI: 0.30- 0.85),p = 0.01	<b>Good</b>	Lower MV TLR in FKB group



# COBIS II Registry

## “KISS” for 1-stent techniques

- Treated with 1-stent technique: N=1,901
- Final kissing ballooning (FKB): N=620 → PSM matched analysis: N=545 pairs

	Propensity-Matched Population			Standardized Difference
	FKB (n = 545)	Non-FKB (n = 545)	p Value	
<b>After MV stenting</b>				
Main vessel				
Proximal MLD	3.07 ± 0.55	3.02 ± 0.58	0.85	9.2
Middle MLD	2.76 ± 0.54	2.71 ± 0.56	0.72	9.6
Distal MLD	2.76 ± 0.49	2.72 ± 0.54	0.85	8.6
Side branch				
Ostial MLD	1.26 ± 0.73	1.25 ± 0.69	0.71	1.3
Distal MLD	2.02 ± 0.69	1.96 ± 0.68	0.67	7.8
<b>Final</b>				
Main vessel				
Proximal MLD				
Middle MLD	2.86 ± 0.50	2.72 ± 0.56	0.001	
Distal MLD	2.83 ± 0.48	2.73 ± 0.55	0.04	
Side branch				
Ostial MLD	1.85 ± 0.62	1.36 ± 0.69	<0.001	
Distal MLD	2.15 ± 0.59	1.99 ± 0.68	0.04	

FKB reduces main vessel TLR, not side branch TLR.  
**“Gentle KISS for MB and SB”**


	Adjusted HR (95% CI)	p
<b>MACE</b>	<b>0.50</b> (0.30-0.85)	<b>0.01</b>
Cardiac death	0.50 (0.11-2.29)	0.37
MI	0.18 (0.01-20.4)	0.48
Stent thrombosis,	0.77 (0.17-3.45)	0.73
	0.91	0.02
<b>Main vessel</b>	<b>0.51</b> (0.28-0.93)	<b>0.03</b>
Side branch	0.57 (0.24-1.37)	0.21

# COBIS II Registry

## Clinical impact of NC balloon

- Use of non-compliant balloon: N=752, 26.0%
- Propensity score-matched analysis: N=710 pairs

	CB	NCB	p
Dissection >type B	1.1%	0.1%	0.046
Angiographic success			
Main vessel	99.0%	98.7%	0.80
Side branch	75.4%	79.7%	0.03
In-hospital MI	0.8%	0%	0.04




# What makes the difference?

Device? Concept? Technique?

- Safer access: More trans-radial approach
- Better stents and better stenting technique
- Better PCI technique: Better kissing, NC balloon, POT
- **Better concept: imaging guidance, SB relevance**
- Better risk stratification: SB occlusion, risk stratification


# COBIS Registry

## IVUS guidance improves outcomes




# COBIS II Registry

## True vs. Non-true bifurcation lesions: Clinical relevance of SB




**Focus on true bifurcation with large SB.**


# How large is large enough?




**% ischemia: 15%**



**% ischemia: 11%**



**% ischemia: 10%**



**% ischemia: 12%**



**DECISION TREE LEARNING** IS THE PROCESS OF CREATING/LEARNING A DECISION TREE FROM TRAINING DATA


**RECURSIVE PARTITIONING**  
IS THE MOST COMMON STRATEGY FOR  
DECISION TREE LEARNING

**ID3 C4.5**  
**CART CHAID**

DECISION TREE LEARNING  
ALGORITHMS BASED ON  
RECURSIVE PARTITIONING


One branch? 2 branch? 3 branch? 2.8mm?  
2.3mm? LCx dominance? D1/2 dominance?  
Non-dominant? .....

.....To train and validate models to predict % FMM ≥ 10%, the entire CCTA dataset was split into training and validation sets (4:1). To build a decision tree model, the training and validation sets were used for **recursive partitioning with 10-fold cross-validation**. **Information gain** was used to selected attributes for **higher nodes**.....



Jeon WK, Koo BK, et al. Eurointervention, In press



# Decision Tree for % FMM $\geq 10\%$



Jeon WK, Koo BK, et al. Eurointervention, In press



# Are you (un)happy with this?




OCT: 18 mo after Cypher

Koo BK, LaDisa J, 2009

# COBIS III Registry


## Clinical relevance of SB opening

### Non-True Bifurcation



Leave alone	1085	979	909	808	619	372
SB opening	212	191	175	151	118	69

### True Bifurcation



Leave alone	600	549	495	434	332	230
SB opening	297	267	244	207	146	90

# What makes the difference?


Device? Concept? Technique?

- Safer access: More trans-radial approach
- Better stents and better stenting technique
- Better PCI technique: Better kissing, NC balloon, POT
- Better concept: imaging guidance, SB relevance
- **Better risk stratification: SB occlusion, risk stratification**

## COBIS II Registry

# Clinical impact of SB occlusion

- Main vessel first stenting strategy: N=2,227
- SB occlusion after MV stenting (TIMI flow <3): N=187, 8.4%



Hahn JY, et al. JACC 2013

# How to avoid SB compromise after MV stenting?

- **How to protect SB?**
  - Jailed wire technique
  - SB predilation
  - Optimal stent sizing, .....

## Predictors of SB occlusion from COBIS II

Variables	OR [95% CI]	p Value
SB DS $\geq$ 50%	2.3 [1.59-3.43]	<0.001
SB lesion length (by 1 mm)	1.0[1.003-1.06]	<0.001
Proximal MV DS $\geq$ 50%	2.3 [1.57-3.50]	0.03
Acute coronary syndrome	1.5 [1.06-2.19]	0.02
Left main lesions	0.3 [0.16-0.72]	0.005

# COBIS II Registry

## Predictor of SB recovery after occlusion

- SB flow recovery: 129 out of 187 occluded patients (69%).

	SB recovery (n=129)	No SB recovery (n=58)	p Value
<b>Bifurcation location</b>			0.65
Left main bifurcation	9 (7.0)	5 (8.6)	
LAD/diagonal	84 (65.1)	40 (69.0)	
LCX/OM	25 (19.4)	7 (12.1)	
RCA bifurcation	11 (8.5)	6 (10.3)	
<b>True bifurcation</b>	94 (72.9)	45 (77.6)	0.49
<b>Jailed wire in the SB</b>	92 (71.3)	31 (53.4)	0.02
<b>SB predilation before MV stenting</b>	45 (34.9)	16 (27.6)	0.33
<b>Guidance of intravascular ultrasound</b>	39 (30.2)	13 (22.4)	0.27
<b>MV stent diameter (mm)</b>	3.0 (3.0-3.5)	3.0 (2.9-3.5)	0.62
<b>MV stent length (mm)</b>	24.0 (20.0-30.0)	24.0 (20.0-32.0)	0.91
<b>MV stent maximal pressure (atm)</b>	12.0 (10.0-15.5)	12.0 (10.0-14.0)	0.57
<b>MV stent to artery ratio</b>	1.2 (1.1-1.3)	1.2 (1.1-1.4)	0.25

# Korean Bifurcation Pooled Cohorts

## Predictors of TVF in 2-stent strategy

- Treated with 2-stent strategy: N=951

	Adjusted HR*	95% CI	p Value
Treated bifurcation in LM	2.09	1.43 – 3.03	<0.001
High SYNTAX score >32	2.00	1.28 – 3.14	0.002
Diabetes mellitus	1.41	1.00 – 1.99	0.05
Second-generation DES	0.26	0.12 – 0.57	0.001
Non-compliant balloon	0.53	0.36 – 0.79	0.002
Final kissing ballooning	0.44	0.29 – 0.68	<0.001

\*Adjusted for age (continuous), acute coronary syndrome as presentation, preprocedural hemoglobin level, pre-procedural creatinine level, bifurcation angle (continuous), multi-vessel coronary disease, transradial approach, intravascular ultrasound, provisional approach, stenting techniques, total stent length in side branch (continuous).

# Conclusion

- COBIS registry started with bifurcation PCI patients since 2004 is still ongoing with dedicated QCA core laboratory/CRO, independent statistical analysis team and event adjudication committee.
- Results of COBIS studies expanded our knowledge on bifurcation treatment and improved the patients' clinical outcomes.
- Ongoing COBIS III study will provide more insights on coronary bifurcation lesions and their treatment.